IgA Nephropathy

Nephrology
12
Pipeline Programs
10
Companies
13
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
8
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 12 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
2 programs
1
1
Intravenous RituximabPhase 4Monoclonal Antibody1 trial
Bardoxolone methyl capsulesPhase 21 trial
Active Trials
NCT03366337Completed103Est. Jan 2019
NCT00498368Completed34Est. Sep 2015
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
AtaciceptPhase 31 trial
Active Trials
NCT04716231Active Not Recruiting376Est. Jul 2028
Novartis
NovartisBASEL, Switzerland
2 programs
1
AtrasentanPhase 21 trial
AtrasentanN/A1 trial
Active Trials
NCT07319585Available
NCT04573920Active Not Recruiting103Est. Oct 2026
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
2 programs
2
Fostamatinib 150 mgPhase 21 trial
Fostamatinib Disodium tablet 100 mgPhase 21 trial
Active Trials
NCT02112838CompletedEst. Nov 2018
NCT02433236Withdrawn
Q32 Bio
Q32 BioMA - Waltham
1 program
1
ADX-097Phase 21 trial
Active Trials
NCT06419205Withdrawn0Est. Jun 2026
Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
1 program
1
APL-2Phase 21 trial
Active Trials
NCT03453619Completed21Est. Aug 2023
Eledon Pharmaceuticals
1 program
1
AT-1501Phase 21 trial
Active Trials
NCT05125068TerminatedEst. Jul 2023
NovelMed Therapeutics
NovelMed TherapeuticsOH - Cleveland
1 program
1
NM8074Phase 21 trial
Active Trials
NCT06454110Not Yet RecruitingEst. Jul 2027
Arrowhead Pharmaceuticals
1 program
1
ARO-CFBPhase 1/21 trial
Active Trials
NCT06209177Active Not Recruiting66Est. Mar 2026
Biohaven
BiohavenNEW HAVEN, CT
1 program
1
BHV-1400Phase 11 trial
Active Trials
NCT07054684RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BiogenIntravenous Rituximab
Vera TherapeuticsAtacicept
NovelMed TherapeuticsNM8074
Q32 BioADX-097
Eledon PharmaceuticalsAT-1501
NovartisAtrasentan
Apellis PharmaceuticalsAPL-2
BiogenBardoxolone methyl capsules
Rigel PharmaceuticalsFostamatinib Disodium tablet 100 mg
Rigel PharmaceuticalsFostamatinib 150 mg
Arrowhead PharmaceuticalsARO-CFB
BiohavenBHV-1400

Clinical Trials (13)

Total enrollment: 703 patients across 13 trials

NCT00498368BiogenIntravenous Rituximab

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

Start: Feb 2009Est. completion: Sep 201534 patients
Phase 4Completed
NCT04716231Vera TherapeuticsAtacicept

Atacicept in Subjects With IgA Nephropathy

Start: Jun 2023Est. completion: Jul 2028376 patients
Phase 3Active Not Recruiting
NCT06454110NovelMed TherapeuticsNM8074

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

Start: Nov 2025Est. completion: Jul 2027
Phase 2Not Yet Recruiting
NCT06419205Q32 BioADX-097

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Start: Jun 2024Est. completion: Jun 20260
Phase 2Withdrawn
NCT05125068Eledon PharmaceuticalsAT-1501

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Start: Mar 2022Est. completion: Jul 2023
Phase 2Terminated
NCT04573920NovartisAtrasentan

Atrasentan in Patients With Proteinuric Glomerular Diseases

Start: Mar 2021Est. completion: Oct 2026103 patients
Phase 2Active Not Recruiting
NCT03453619Apellis PharmaceuticalsAPL-2

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Start: Feb 2018Est. completion: Aug 202321 patients
Phase 2Completed
NCT03366337BiogenBardoxolone methyl capsules

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

Start: Dec 2017Est. completion: Jan 2019103 patients
Phase 2Completed
NCT02433236Rigel PharmaceuticalsFostamatinib Disodium tablet 100 mg

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

Start: Sep 2015
Phase 2Withdrawn
NCT02112838Rigel PharmaceuticalsFostamatinib 150 mg

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Start: Oct 2014Est. completion: Nov 2018
Phase 2Completed
NCT06209177Arrowhead PharmaceuticalsARO-CFB

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease

Start: Apr 2024Est. completion: Mar 202666 patients
Phase 1/2Active Not Recruiting
NCT07054684BiohavenBHV-1400

Study of BHV-1400 in IgA Nephropathy

Start: Jul 2025Est. completion: Jul 2027
Phase 1Recruiting
NCT07319585NovartisAtrasentan

Managed Access Programs for EXV811, Atrasentan

N/AAvailable

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 703 patients
10 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)